Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Tuesday 10 November, 2009

Lipoxen PLC

Additional Listing

RNS Number : 2637C
Lipoxen PLC
10 November 2009

Lipoxen PLC

("Lipoxen" or "the Company")

Additional listing

London, UK, 10 November 2009 - Lipoxen PLC (AIM:LPX) a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and siRNA delivery, announces that application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 187,145 ordinary shares of 0.5p each (the "New Ordinary Shares").

The New Ordinary Shares are being admitted pursuant to the exercise of options under the Lipoxen Plc Unapproved Share Option Plan.

It is expected that dealings in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 11 November 2009.



Lipoxen plc

+44 (0)20 7691 3583 

M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång 

Noble & Company

+44 (0) 20 7763 2200 

John Llewellyn-Lloyd / Sam Reynolds  

Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon, Rebecca Skye Dietrich, Catherine Breen

This information is provided by RNS
The company news service from the London Stock Exchange